Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6088 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AZD6088 oral solution |
| B | EXPERIMENTAL | Placebo oral solution |
| Name | Type | Description |
|---|---|---|
| AZD6088 | DRUG | Oral solution. Each subject will receive a single-dose of AZD6088. |
| Placebo | DRUG | Oral solution. Each subject will receive a single-dose of placebo. |
Inclusion Criteria: * Caucasian male and non-fertile female healthy volunteers aged ≥18 to ≤55 years with suitable veins for cannulation or repeated venipuncture. * Clinically normal physical findings including supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by t...
AZD6088 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and the compound remains in early clinical development.
AZD6088 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 study of the compound conducted in the United Kingdom. No partner or licensing arrangement for AZD6088 has been announced.
AZD6088 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
AZD6088 has been evaluated in a single Phase 1 study, NCT00931541, titled AZD6088 Single Ascending Dose Study. The trial enrolled 35 healthy adult volunteers in the United Kingdom, used a randomized, double-blind, controlled design, and has been completed.
No. AZD6088 is an investigational drug in Phase 1 development and has not been approved by the FDA. Its only recorded clinical study, NCT00931541, was a single ascending dose trial in healthy volunteers that has been completed, with no active trials currently listed.
AZD6088 is an investigational small molecule being studied by AstraZeneca PLC, but the specific indication it is intended to treat has not been publicly disclosed. Its completed Phase 1 trial, NCT00931541, enrolled healthy volunteers rather than patients with a defined disease.